Dive into the archives.
- Newly Published Data Show Copaxone Promoted Remyelination of Damaged Axons
The purpose of this study was to examine the effect of glatiramer acetate on oligodendrogenesis (the formation of myelin-producing glial cells in the central nervous system) and myelin formation in damaged nerve cells in mice
The mice were subjected to lysolecithin-induced demyelination of the spinal cord, then treated daily for seven days with a 2mg injection [...]
- Teva Sues Mylan Over MS Drug Copaxone
Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. Teva announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the [...]
- Copaxone Used for First-Episode/CIS Halves MS Risk
PARIS — Early treatment with a key drug to fight multiple sclerosis (MS) nearly halves the risk of progression to the full-blown disease, according to a study published online on Wednesday by The Lancet.
The treatment, glatiramer acetate, marketed as Copaxone, was tested in 16 countries among 481 patients with a telltale lesion in the central [...]
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Hot off the AAN Press: Laquinimod, New Data, Novel MOA
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
-Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new [...]
- Hot off the AAN Press: Study Suggests Copaxone has Protective Effects
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
- New Data Presented at 61st Annual Meeting of the American Academy of Neurology -
JERUSALEM–New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) [...]
- The Age of Orals: Who Will Win the Race to the Market?
Jan 23, 2009
Oral Cladribine Reduces MS Relapses in Phase 3 Clinical Trial
Oral cladribine (EMD Serono) reduced the relapse rate significantly more than inactive placebo in the phase 3 “CLARITY” study of 1,326 people with relapsing-remitting MS. These initial results – the first from any phase 3 study of oral therapy for MS — are reported [...]
